文献速递系统性红斑狼疮其他结缔组织病类风湿关节炎

推进自身免疫性风湿病治疗:CAR-T细胞疗法的证据、安全性与未来方向

Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions.
PubMed 文献 · Semin Arthritis Rheum · 2024-05-24

本叙述性综述检索文献,探讨CAR-T细胞疗法在难治性自身免疫性风湿病中的现有证据、潜在安全性、局限性、潜在改良与未来方向。CAR-T细胞已用于系统性红斑狼疮、抗合成酶综合征和系统性硬化症等难治性患者并显示显著改善,临床前及体外研究亦支持其对抗中性粒细胞胞质抗体相关性血管炎和类风湿关节炎的疗效;细胞因子释放综合征等不良事件需谨慎监测,但疗法似乎耐受性良好,成本、CAR-T细胞耗竭所致持久性及生产复杂性等挑战仍存。

要点

  • CAR-T细胞疗法在难治性系统性红斑狼疮、抗合成酶综合征和系统性硬化症患者中显示显著改善。
  • 临床前及体外研究支持CAR-T细胞对抗中性粒细胞胞质抗体相关性血管炎和类风湿关节炎的疗效。
  • 细胞因子释放综合征等不良事件需谨慎监测,但疗法似乎耐受性良好;成本、持久性与生产复杂性等挑战仍存。

核心结论

  • CAR-T细胞疗法对难治性自身免疫性风湿病显示出高效性。
  • 目前未报告显著警示信号,但在将CAR-T细胞疗法适应于自身免疫性风湿病时,实现疗效与安全性之间的平衡至关重要。
  • 技术进步在改善该疗法向患者交付方面具有显著潜力,从而为患者确保更安全、更有效的疾病控制。

研究设计与样本

  • 本文为叙述性综述,通过文献检索探讨CAR-T细胞在自身免疫性风湿病中的现有证据、潜在安全性、局限性、潜在改良与未来方向。

主要发现

  • CAR-T细胞疗法已用于难治性自身免疫性风湿病患者,包括系统性红斑狼疮、抗合成酶综合征和系统性硬化症,显示出显著改善。
  • 显著应答包括临床症状改善、血清自身抗体滴度降低以及疾病活动度持续缓解。
  • 使用动物和人类样本的临床前及体外研究支持CAR-T细胞对抗中性粒细胞胞质抗体相关性血管炎和类风湿关节炎的疗效,并阐述其潜在机制。
  • 细胞因子释放综合征等不良事件需谨慎监测,但该疗法似乎耐受性良好。
  • 挑战持续存在,包括成本、因潜在CAR-T细胞耗竭导致的持久性以及生产复杂性。

局限性

  • 挑战持续存在,包括成本、因潜在CAR-T细胞耗竭导致的持久性以及生产复杂性,促使开发创新解决方案以进一步增强CAR-T细胞疗法在自身免疫性风湿病中的可及性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite advancements in managing autoimmune rheumatic diseases (ARDs) with existing treatments, many patients still encounter challenges such as inadequate responses, difficulty in maintaining remission, and side effects. Chimeric Antigen Receptor (CAR) T-cell therapy, originally developed for cancer, has now emerged as a promising option for cases of refractory ARDs. METHODS: A search of the literature was conducted to compose a narrative review exploring the current evidence, potential safety, limitations, potential modifications, and future directions of CAR-T cells in ARDs. RESULTS: CAR-T cell therapy has been administered to patients with refractory ARDs, including systemic lupus erythematosus, antisynthetase syndrome, and systemic sclerosis, demonstrating significant improvement. Notable responses include enhanced clinical symptoms, reduced serum autoantibody titers, and sustained remissions in disease activity. Preclinical and in vitro studies using both animal and human samples also support the efficacy and elaborate on potential mechanisms of CAR-T cells against antineutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis. While cautious monitoring of adverse events, such as cytokine release syndrome, is crucial, the therapy appears to be highly tolerable. Nevertheless, challenges persist, including cost, durability due to potential CAR-T cell exhaustion, and manufacturing complexities, urging the development of innovative solutions to further enhance CAR-T cell therapy accessibility in ARDs. CONCLUSIONS: CAR-T cell therapy for refractory ARDs has demonstrated high effectiveness. While no significant warning signs are currently reported, achieving a balance between therapeutic efficacy and safety is vital in adapting CAR-T cell therapy for ARDs. Moreover, there is significant potential for technological advancements to enhance the delivery of this treatment to patients, thereby ensuring safer and more effective disease control for patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ohno R, Nakamura A. Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions. Semin Arthritis Rheum. 2024. PMID: 38810569. doi:10.1016/j.semarthrit.2024.152479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。